← Back to Clinical Trials
Recruiting NCT07333222

NCT07333222 Functional and Quality of Life Effects of the Mollii Neuromodulatory Suit in Patients With Stroke and Multiple Sclerosis

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07333222
Status Recruiting
Phase
Sponsor Somogy Megyei Kaposi Mór Teaching Hospital
Condition Stroke
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2026-01-12
Primary Completion 2026-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 99 Years
Study Type INTERVENTIONAL
Interventions
the Mollii garment with active stimulationMollii neuromodulation garment, but the stimulation program is not activated (placebo)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2026-01-12 with a primary completion date of 2026-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

* Objective assessment of clinical symptoms resulting from stroke, as well as changes in mobility and quality of life, and determination of changes resulting from therapies * Objective assessment of the quality of life, functionality, and clinical symptoms of patients with multiple sclerosis (MS) and determination of changes resulting from therapies * Comparison of measured data from the two main neurological patient groups (stroke, multiple sclerosis) and follow-up of changes in relation to themselves and each other. * Mapping the role of the placebo effect in neuromodulation devices by comparing subjective and objective outcomes. * Analyzing the expectations and experiences of patients receiving placebo treatment using quality of life questionnaires. * Analyzing the effects of the Mollii suit among subgroups of MS and stroke patients. * Assessing the safety, possible side effects, and tolerability of the Mollii suit. * Mapping changes in gait pattern due to the effects of therapy using 3D motion analysis. * Examining the maintenance effects of neuromodulation during a 1-month follow-up.

Eligibility Criteria

Inclusion Criteria: * suffered a first ischemic stroke, diagnosed by a neurologist based on CT or MR imaging * neurological examination revealed mobility and postural limitations * confirmed multiple sclerosis diagnosed by a neurologist based on MRI imaging Exclusion Criteria: * multiple strokes in medical history * systolic blood pressure less than 120 or higher than 160 mmHg * orthostatic hypotension * arotid artery stenosis * severe heart disease * hemophilia * traumatic brain injury * seizure disorder * untreated diabetes * abnormal electroencephalography * abnormal blood panel * use of sedatives * irregular medication use * severe aphasia (Western Aphasia Battery ≤ 25) * severe visual or hearing impairment * severe sensory dysfunction * severe orthopedic problems * other neurological conditions affecting motor function * alcoholism * drug use * smoking after diagnosis of stroke * unable to walk at least 10 m with or without assistance in 6 minutes * BBS score ≤ 32 * BI score ≤ 70 * current participation in individual or group exercise program outside of standard physical therapy

Contact & Investigator

Central Contact

Barbara Kopácsi

✉ kbarbi0108@gmail.com

📞 +36308340545

Principal Investigator

József Dr. habil Tollár

PRINCIPAL INVESTIGATOR

Somogy County Kaposi Mór Teaching Hospital

Frequently Asked Questions

Who can join the NCT07333222 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07333222 currently recruiting?

Yes, NCT07333222 is actively recruiting participants. Contact the research team at kbarbi0108@gmail.com for enrollment information.

Where is the NCT07333222 trial being conducted?

This trial is being conducted at Kaposvár, Hungary.

Who is sponsoring the NCT07333222 clinical trial?

NCT07333222 is sponsored by Somogy Megyei Kaposi Mór Teaching Hospital. The principal investigator is József Dr. habil Tollár at Somogy County Kaposi Mór Teaching Hospital. The trial plans to enroll 40 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology